Quest Diagnostics refinances long-term debt:
This article was originally published in Clinica
Executive Summary
Quest Diagnostics plans to refinance the majority of its long-term debt and will take a special charge of up to $45 million. The Teterboro, New Jersey company has begun a cash tender offer for the outstanding $150 million principal amount of its 10.75% senior subordinated notes, which are due in 2006. Quest has also received commitments for $650 million of unsecured bank debt from a group of banks led by Bank of America and UBS Warburg.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.